clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kuwayama H et al. | Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. | 2007 | Aliment. Pharmacol. Ther. | pmid:17439512 |
Wong WM et al. | Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese. | 2005 | Aliment. Pharmacol. Ther. | pmid:15644048 |
Van Oijen AH et al. | Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930892 |
Hurenkamp GJ et al. | Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930901 |
Wheeldon TU et al. | Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848630 |
Lai KC et al. | Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930902 |
Pilotto A et al. | Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930903 |
Kihira K et al. | Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930904 |
Kamada T et al. | Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. | 2000 | Aliment. Pharmacol. Ther. | pmid:10930905 |
Dalla Libera M et al. | High effectiveness and safety of one-week antibiotic regimen in Helicobacter pylori eradication. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730251 |
Labenz J et al. | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8730252 |
Gatta L et al. | A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. | 2005 | Aliment. Pharmacol. Ther. | pmid:15963079 |
Nseir W et al. | Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study. | 2012 | Aliment. Pharmacol. Ther. | pmid:22646167 |
Wong BC et al. | Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. | 2001 | Aliment. Pharmacol. Ther. | pmid:11380322 |
Meier R et al. | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. | 2001 | Aliment. Pharmacol. Ther. | pmid:11380323 |
Kamberoglou D et al. | Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. | 2001 | Aliment. Pharmacol. Ther. | pmid:11552924 |
Harb AH et al. | Systematic review and meta-analysis: full- vs. half-dose anti-microbials in clarithromycin-based regimens for Helicobacter pylori eradication. | 2015 | Aliment. Pharmacol. Ther. | pmid:26011564 |
al-Assi MT et al. | Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986970 |
Neri M et al. | Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. | 1994 | Aliment. Pharmacol. Ther. | pmid:7986974 |
Spinzi G et al. | Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9146769 |
Peterson WL | The role of antisecretory drugs in the treatment of Helicobacter pylori infection. | 1997 | Aliment. Pharmacol. Ther. | pmid:9146787 |
Nada T et al. | DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298604 |
Kaneko F et al. | High prevalence rate of Helicobacter pylori resistance to clarithromycin during long-term multiple antibiotic therapy for chronic respiratory disease caused by non-tuberculous mycobacteria. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298607 |
Sierra F et al. | Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. | 2013 | Aliment. Pharmacol. Ther. | pmid:23656465 |
Masaoka T et al. | Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298608 |
Okudaira K et al. | Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. | 2005 | Aliment. Pharmacol. Ther. | pmid:15710002 |
Kondo Y et al. | Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. | 2004 | Aliment. Pharmacol. Ther. | pmid:15298609 |
Lai KC et al. | Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641502 |
Zullo A et al. | High eradication rates of Helicobacter pylori with a new sequential treatment. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641522 |
Chiba N et al. | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:14984382 |
de Francesco V et al. | Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction. | 2006 | Aliment. Pharmacol. Ther. | pmid:16423002 |
Di Mario F et al. | Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16611285 |
Madisch A et al. | Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441467 |
Borody TJ et al. | Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection. | 2006 | Aliment. Pharmacol. Ther. | pmid:16441468 |
Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786632 |
Fock KM et al. | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10651664 |
Wong BC et al. | One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207516 |
Fakheri H et al. | Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207517 |
Lamouliatte H et al. | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10571611 |
Nagahara A et al. | Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11207518 |
Bardhan KD et al. | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632646 |
Cammarota G et al. | Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632648 |
Fischbach LA et al. | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569109 |
Yousfi MM et al. | Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. | 1995 | Aliment. Pharmacol. Ther. | pmid:7605865 |
Axon AT et al. | Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042977 |
Labenz J et al. | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042978 |
Choi IJ et al. | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856089 |
Bazzoli F et al. | Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:11856090 |
Park HG et al. | Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. | 2012 | Aliment. Pharmacol. Ther. | pmid:22066530 |
Kim JS et al. | Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860410 |
Malfertheiner P et al. | Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860399 |
Poon SK et al. | Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860412 |
Peitz U et al. | High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. | 2002 | Aliment. Pharmacol. Ther. | pmid:11860415 |
Barth J and Hahne W | Review article: rabeprazole-based therapy in Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849125 |
Qasim A and O'Morain CA | Review article: treatment of Helicobacter pylori infection and factors influencing eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11849124 |
Sheu BS et al. | Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:12197847 |
Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
Spadaccini A et al. | Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798805 |
Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
Bortolotti M et al. | Effects of oral clarithromycin and amoxycillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1998 | Aliment. Pharmacol. Ther. | pmid:9798808 |
Calvet X et al. | A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. | 2000 | Aliment. Pharmacol. Ther. | pmid:10792124 |
John Albert M et al. | High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. | 2006 | Aliment. Pharmacol. Ther. | pmid:17059517 |
Spinzi GC et al. | Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663722 |
Villoria A et al. | Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. | 2008 | Aliment. Pharmacol. Ther. | pmid:18644011 |
Bazzoli F et al. | Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. | 1998 | Aliment. Pharmacol. Ther. | pmid:9663723 |
O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
Goodgame RW et al. | Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736715 |
Malfertheiner P et al. | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752349 |
Gené E et al. | Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12752350 |
Sheu BS et al. | The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755841 |
Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121908 |
Isomoto H et al. | 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121910 |
Canducci F et al. | A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121911 |
Toracchio S et al. | Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:11121913 |
Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
Pilotto A et al. | Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971305 |
Gudjonsson H et al. | High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9845401 |
Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
Gisbert JP et al. | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. | 2006 | Aliment. Pharmacol. Ther. | pmid:16556172 |
Tam YH et al. | Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803605 |
Kawabata H et al. | Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. | 2003 | Aliment. Pharmacol. Ther. | pmid:12534411 |
Gisbert JP et al. | Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012477 |
Catalano F et al. | Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012478 |
Gomollón F et al. | Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. | 2000 | Aliment. Pharmacol. Ther. | pmid:11012479 |
Mason JM et al. | Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. | 2008 | Aliment. Pharmacol. Ther. | pmid:18793340 |
Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
Nista EC et al. | Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:12969089 |
De Francesco V et al. | Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. | 2004 | Aliment. Pharmacol. Ther. | pmid:14871280 |
Tankovic J et al. | Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11328266 |
Koivisto TT et al. | First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens. | 2005 | Aliment. Pharmacol. Ther. | pmid:15771764 |
Klok RM et al. | Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966514 |
Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
Tursi A et al. | Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8791952 |
Feydt-Schmidt A et al. | Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. | 2002 | Aliment. Pharmacol. Ther. | pmid:12452940 |
Isomoto H et al. | High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848631 |
Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
McNulty CA et al. | Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? | 2012 | Aliment. Pharmacol. Ther. | pmid:22469191 |